Global biopharmaceutical company Alkermes has appointed Mark Namchuk as Senior Vice President of Research, Pharmaceutical and Nonclinical Development.
Namchuk will be responsible for advancing the company’s early-stage product pipeline. He will join Alkermes' executive management team and report to Elliot Ehrich, Senior Vice President of Research & Development and Chief Medical Officer.
He joins Alkermes with nearly 20 years of experience in integrated R&D and drug discovery.
Most recently, Namchuk was Senior Vice President and Interim Global Head of Research at Vertex Pharmaceuticals, leading a group of more than 450 researchers in the discovery of medicines in the areas of infectious disease, oncology, inflammatory diseases, neurology and cystic fibrosis. He has built and led departments supporting early pharmaceutical R&D, including medicinal chemistry, protein biophysics, in vitro and in vivo pharmacology, drug metabolism, pharmacokinetics, and clinical and preclinical biomarkers.
Earlier in his career, Namchuk was head of the biochemistry group at Cubist Pharmaceuticals.
